TABLE 1

Characteristics of the study population stratified by the tuberculin skin test (TST) and the QuantiFERON-TB results

TotalTSTQuantiFERON-TB
PositiveNegativePositiveNegative
Patients1492212721127
Age years median (interquartile range)62 (54–70)59 (53–66)62 (54–70)64 (63–73)60 (53–69)#
Female94 (63.1%)12 (54.5%)82 (64.6%)11 (52.4%)82 (64.6%)
Type of cancer diagnosis by location
 Soft tissues and breast30 (20.1%)4 (18.2%)26 (20.5%)3 (14.3%)27 (21.3%)
 Thyroid28 (18.8%)4 (18.2%)24 (18.9%)5 (23.8%)23 (18.1%)
 Gastrointestinal22 (14.8%)2 (9.1%)20 (15.7%)3 (14.3%)18 (14.2%)
 Haematologic15 (10.1%)3 (13.6%)12 (9.4%)3 (14.3%)12 (9.4%)
 Renal and urinary tract13 (8.7%)2 (9.1%)11 (8.7%)3 (14.3%)10 (7.9%)
 Lung9 (6%)2 (9.1%)7 (5.5%)1 (4.8%)8 (6.3%)
 Gynaecological9 (6%)2 (9.1%)7 (5.5%)1 (4.8%)8 (6.3%)
 Head and neck (not thyroid)6 (4%)1 (4.5%)5 (3.9%)1 (4.8%)5 (3.9%)
 Other17 (11.4%)2 (9.1%)15 (11.8%)1 (4.8%)16 (12.6%)
Cancer status
 Partial or complete remission62 (41.6%)8 (36.4%)54 (42.5%)11 (52.4%)51 (40.2%)
 Current management with palliative chemotherapy34 (22.8%)6 (27.3%)28 (22%)5 (23.8%)29 (22.8%)
 Current management with other treatments16 (10.7%)2 (9.1%)14 (11%)1 (4.8%)15 (11.8%)
 Progression, with follow-up18 (12.1%)4 (18.2%)14 (11%)2 (9.5%)16 (12.6%)
 Initial staging, before the beginning of treatment10 (6.7%)2 (9.1%)8 (6.3%)2 (9.5%)8 (6.3%)
 Current management with curative chemotherapy7 (4.7%)7 (5.5%)6 (4.7%)
 Missing results2 (1.3%)
Scar from BCG vaccine100 (67.1%)14 (63.6%)86 (67.7%)11 (52.4%)89 (70.1%)
Comorbidities associated with immunosuppression
 Treatment with other immunosuppressants in the last 3 months35 (23.5%)4 (18.2%)31 (24.4%)3 (14.3%)31 (24.4%)
 Corticosteroid use for >90 days, >15 mg prednisone4 (2.7%)4 (3.1%)4 (3.1%)
 Insulin-dependent diabetes3 (2%)3 (2.4%)3 (2.4%)
 History of haematopoietic stem cell transplant2 (1.3%)1 (4.5%)1 (0.8%)2 (1.6%)
 Chronic kidney disease2 (1.3%)2 (1.6%)2 (1.6%)
 Cases with two comorbidities8 (5.4%)2 (9.1%)6 (4.7%)3 (14.3%)5 (3.9%)
Lymphopenia23 (15.4%)3 (13.6%)20 (15.7%)4 (19%)19 (15%)
 Missing lymphocyte results26 (17.4%)

The indeterminate results of QuantiFERON-TB were excluded for statistical analyses. BCG: bacille Calmette–Guérin. #: p=0.02, logistic regression between QuantiFERON-TB negative and positive results groups; : lymphocyte count <1000 per mm3.